Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jan 2;128(1):110-112.
doi: 10.1172/JCI98617. Epub 2017 Dec 4.

Antisense oligonucleotides offer hope to patients with Charcot-Marie-Tooth disease type 1A

Michael E Shy
Comment

Antisense oligonucleotides offer hope to patients with Charcot-Marie-Tooth disease type 1A

Michael E Shy. J Clin Invest. .

Abstract

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common heritable peripheral neuropathy and results from a duplication on chromosome 17 that results in an extra copy and increased dosage of peripheral myelin protein 22 (PMP22). Zhao et al., in this issue of the JCI, successfully utilized antisense oligonucleotides (ASOs) to reduce PMP22 and ameliorated neuropathy in both mouse and rat models of CMT1A. These data confirm that strategies to reduce PMP22 have potential as effective therapeutic approaches for CMT1A and lay the groundwork for clinical trials in humans afflicted with this chronic, debilitating neurodegenerative disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M.E. Shy serves as a consultant for Alnylam Pharmaceuticals and Acceleron Pharma.

Figures

Figure 1
Figure 1. ASO therapy for patients with CMT1A causes demyelination that over time leads to secondary axonal degeneration and ff accumulation in the muscle.
ASO binding to PMP22 mRNA may alleviate demyelination, but may not reduce axonal degeneration and ff accumulation in muscle that have already occurred, supporting the use of ASO as early as feasible to minimize these secondary complications of CMT1A.
See this image and copyright information in PMC

Comment on

References

    1. Lupski JR, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66(2):219–232. doi: 10.1016/0092-8674(91)90613-4. - DOI - PubMed
    1. Timmerman V, et al. The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication. Nat Genet. 1992;1(3):171–175. doi: 10.1038/ng0692-171. - DOI - PubMed
    1. Zhao HT, et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J Clin Invest. 2018;128(1):359–368. doi: 10.1172/JCI96499. - DOI - PMC - PubMed
    1. Pareyson D, et al. Does CMT1A homozygosity cause more severe disease with root hypertrophy and higher CSF proteins? Neurology. 2003;60(10):1721–1722. doi: 10.1212/01.WNL.0000059262.34846.8A. - DOI - PubMed
    1. Shy M, et al. The hereditary motor and sensory neuropathies: an overview of the clinical, genetic, electrophysiologic and pathlogic features. In: Dyck P, Thomas PK, eds. Peripheral Neuropathy. 4th ed. Philadelphia, Pennsylvania, USA: WB Saunders; 2005:1623–1658.

Publication types